Key result
Low-dose tirofiban after successful endovascular reperfusion improved 90-day functional independence without a statistically significant increase in symptomatic intracranial haemorrhage.
Why the study?
Does low-dose tirofiban improve 90 day functional independence in patients with large-vessel occlusion stroke after successful endovascular reperfusion?
Does low-dose tirofiban improve 90 day functional independence in patients with large-vessel occlusion stroke after successful endovascular reperfusion?
Low-dose tirofiban after successful thrombectomy for large-vessel occlusion stroke may improve 90-day functional independence without significantly increasing symptomatic intracranial hemorrhage.
Despite successful thrombectomy, many patients with large-vessel occlusion stroke remain functionally dependent. The ATTRACTION trial evaluated low-dose tirofiban after successful endovascular reperfusion and showed a modest improvement in 90 day functional independence without a statistically significant increase in symptomatic intracranial haemorrhage. The benefit appeared greater in patients with large-artery atherosclerosis and possibly those with incomplete reperfusion, whereas patients with cardioembolic stroke showed less favourable profiles. Compared with previous negative adjunctive antithrombotic trials, ATTRACTION highlights the importance of timing, dose, and delivery route. Further studies are needed to refine patient selection and balance functional benefit against haemorrhagic risk.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) conducted an editorial in large-vessel occlusion stroke. low-dose tirofiban was evaluated on 90 day functional independence. Low-dose tirofiban after successful endovascular reperfusion improved 90-day functional independence without a statistically significant increase in symptomatic intracranial haemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: